Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:32am, Wednesday, 23'rd Nov 2022
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly: Don't Take This Medicine
11:07am, Monday, 21'st Nov 2022
Eli Lilly and Company is fairly new to the dividend growth club. The company is finally growing robustly again.
‘More work to do': Eli Lilly admits insulin pricing could be lower amid Twitter chaos
01:18pm, Saturday, 19'th Nov 2022
Furor over platform's verified profiles may have done some good, but challenges still plague the site after a mass worker exodus
Final Trades: Nvidia, Uber, Eli Lilly & more
09:05am, Saturday, 19'th Nov 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Eli Lilly CEO David Ricks on positive Alzheimer's drug trial data
07:10am, Saturday, 19'th Nov 2022
Eli Lilly said on Monday a trial of its experimental Alzheimer's drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage vic
Eli Lilly's Alzheimer's drug gets FDA breakthrough designation
02:34am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports on how Eli Lilly's will seek FDA approval this year for its Alzheimer's drug.
How Markets Have Fared Under a Divided Congress
01:32pm, Thursday, 17'th Nov 2022
Markets typically applaud the 'certainty' that comes with a split Congress.
American Resources appoints former Eli Lilly executive and Indiana politician Daniel Hasler to board of ReElement Technologies
09:59am, Thursday, 17'th Nov 2022
American Resources Corporation (NASDAQ:AREC) has added former Eli Lilly executive Daniel Hasler to the board of directors at its wholly- owned subsidiary, ReElement Technologies. The appointment come
Eli Lilly (LLY) Stock Up 26.7% YTD: What's in Store for 2023?
09:47am, Wednesday, 16'th Nov 2022
Lilly (LLY) expects to launch five new medicines by 2023-end, including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Four Healthcare Stocks To Watch This Week
08:18am, Wednesday, 16'th Nov 2022
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.
Is Eli Lilly Stock a Buy After Last Week's Twitter Prank?
05:52am, Tuesday, 15'th Nov 2022
Forget the Twitter tumult. Lilly is a verified winner.
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments
02:34pm, Monday, 14'th Nov 2022
Biogen's BIIB, +4.96% stock is rising again as investors double down on the company's promising yet still experimental treatment for Alzheimer's disease.
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads
01:20pm, Monday, 14'th Nov 2022
Eli Lilly reportedly is pulling advertising from Twitter after a fake account promised free insulin in a fiasco that depressed LLY stock. The post Eli Lilly's Twitter Fiasco Continues As Drugmaker Rep
Eli Lilly stock plunged after fake blue check tweet
12:28pm, Monday, 14'th Nov 2022
Yahoo Finance Live anchors discuss the decline in stock for Eli Lilly after an unofficial verified account tweeted that insulin was now free.
Eli Lilly stock starts on front foot after rival Alzheimer trial fails
10:09am, Monday, 14'th Nov 2022
Eli Lilly and Co (NYSE:LLY) stock was moving higher as Roche revealed that an experimental rival treatment for Alzheimer's failed in a Phase III clinical trial. Roche earlier today announced that its
